News and Announcements
4Dx Ltd – First of Its Kind Four-Dimensional X-Ray Lung Imaging
- Published March 05, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
4Dx Limited is a medical technology start-up based in Melbourne, Australia, established to commercialise four-dimensional lung imaging technology: 4DxV.
- Revolutionary diagnostic delivering high resolution, quantitative functional information with low radiation dose as compared to CT and non invasive scanning
- Provides unprecedented levels of detail for the diagnosis and monitoring of debilitating respiratory conditions such as COPD, Cystic Fibrosis, and Asthma.
- Technology that will improve millions of lives through earlier disease detection and more accurate monitoring of chronic respiratory conditions.
Conceived by 4Dx CEO Andreas Fouras and developed by his research group, the Laboratory for Dynamic Imaging at Monash University, this four-dimensional X-ray imaging technology maps the motion and airflow within the breathing lung. This provides information on regional lung function not available in today’s medical clinics.
Initially, its use will be in radiotherapy applications in the fight against cancer. Our four-dimensional X-ray imaging technology will provide invaluable functional information to improve patient outcomes through better treatment planning and monitoring of treatment effectiveness.
The key market for this patented technology will be through the delivery of high-resolution, quantitative function from low dose and non-invasive scanning. Its far reaching potential provides unprecedented levels of detail for the diagnosis and monitoring of debilitating respiratory conditions such as asthma, COPD, cystic fibrosis, and lung cancer.
4Dx is set for an exciting 12 months with the expectation of the publication of major clinical trial results and FDA clearance of its first product. The completion of these major milestones will demonstrate the clinical and commercial value of this technology and positions the company for IPO within the next 24 months.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
